AI CuratorAI-generated

Research summary · 5 d ago

AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal

Human Multiple Sclerosis Patients

In a study of 316 MS patients, higher levels of sEBNA1-IgG were linked to increased CSF leukocyte counts, more frequent pleocytosis, and higher rates of CSF-specific OCB compared to those with lower levels. Notably, sEBV-CA-IgG levels did not show correlations with CSF parameters but were associated with a higher total IgG index.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42898310)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: EBV
Evidence strength: Not graded
Outcome: Not reported

Why it matters

These findings suggest a potential association between EBV-specific antibodies and certain inflammatory markers in MS, which may help elucidate the role of EBV in disease progression.

What this does not prove

The study does not conclusively show the role of intrathecal EBV-specific antibody production regarding basic CSF inflammatory or barrier parameters.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 316 · number of MS patients analyzed
Randomised: No
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-05
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: 316 MS patients from Switzerland and Sweden
Size of effect: sEBNA1-IgG levels associated with a 2.54-fold higher CSF leukocyte count and 2.73-fold higher odds for pleocytosis
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidenceHigh EBV-reactive IgG levels in serum are linked to typical inflammatory cerebrospinal fluid features in multiple sclerosis. ↗DOI: 10.3389/fimmu.2026.1929166

Supporting passages (12)

subjectsHuman

sample size316

sample size basisMETHODS: We analyzed paired serum and cerebrospinal fluid (CSF) samples from 316 MS patients from Switzerland and Sweden.

randomizedNo

publication date2026-10-05

findingsRESULTS: sEBNA1-IgGhi levels were associated with higher CSF leukocyte counts (median 6.0 vs 3.0 cells/µL; q=0.022), more frequent pleocytosis (55.7% vs 37.6%; q=0.022), and higher rate of CSF-specific OCB (93.7% vs 79.3%; q=0.029) compared to lower sEBNA1-IgG levels.

limitationsIntrathecal EBV-specific antibody production was uncommon and not associated with basic CSF inflammatory or barrier parameters.

mechanismsEBV

population316 MS patients from Switzerland and Sweden

effect sizeIn age- and sex-adjusted models, a 10-fold increase in sEBNA1-IgG levels was associated with a 2.54-fold higher CSF leukocyte count (β=0.405, 95% CI 0.217-0.592, p=2.86×10-5) and 2.73-fold higher odds for pleocytosis (OR = 2.73, 95% CI 1.59-4.71, p=2.83×10-4), whereas sEBV-CA-IgG showed no significant correlation.

peer reviewedPublication types: Journal Article; Research Support, Non-U.S. Gov't

subjectsMeSH terms: Humans; Immunoglobulin G; Female; Multiple Sclerosis; Male; Herpesvirus 4, Human; Antibodies, Viral; Adult; Epstein-Barr Virus Infections; Middle Aged; Epstein-Barr Virus Nuclear Antigens; Capsid Proteins; Antigens, Viral

AI assessment, not yet reviewed by a person · version 3 · Community votes are separate from evidence review.